We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Postoperative Biomarker Found for Venous Thromboembolism

By LabMedica International staff writers
Posted on 20 Aug 2013
The D-dimer test is often used to rule out the presence of venous thromboembolism, but the test has been considered unreliable in postoperative patients because D-dimer levels may rise after surgery.

The presence of deep vein thrombosis (DVT) or pulmonary embolism (PE), both manifestations of venous thromboembolism, can be detected by performing the D-dimer test. More...
D-dimer is a fibrin degradation product, which is produced when a blood clot or thrombus dissolves.

Scientists at the University of Halle (Germany) conducted a single-center prospective study between April 2010 and February 2012 in patients undergoing elective surgery that involved craniotomy. The study sample consisted of 59 female and 42 male patients ranging in age from 18 to 82 years. Doppler ultrasonography was used to directly detect the presence of thrombus in the patient's lower extremities. If DVT was identified, the location of this disorder was also noted to determine the associated risk of PE.

Plasma levels of D-dimer in all patients were evaluated preoperatively and on the 3rd, 7th, and 10th days postoperatively with the INNOVANCE D-dimer assay (Siemens; Erlangen, Germany). The investigators found that a D-dimer threshold of 2 mg/L indicated venous thromboembolism with a sensitivity of 95.3%, a specificity of 74.1%, a negative predictive value of 95.6%, and a positive predictive value of 73.2%. Only two patients with venous thromboembolism had D-dimer levels lower than 2 mg/L. The D-dimer threshold for PE would appear to be even higher; in this small group of nine patients the mean D-dimer level was 7.14 mg/L.

The authors concluded that using a threshold of 2 mg/L, D-dimer levels will indicate venous thromboembolism in patients after craniotomy with high sensitivity and specificity. Pulmonary embolism seems to be indicated by even higher D-dimer levels. Julian Prell, MD, the lead author, said, “We were honestly surprised by the clarity of our own results, which strongly contradict the established doctrine. Before this study, D-dimer plasma levels were considered to be completely unreliable in the postoperative period. Now, screening for venous thromboembolism using D-dimer plasma levels appears to be very straightforward and clinically applicable.” The study was published on August 6, 2013, in the Journal of Neurosurgery.

Related Links:
University of Halle
Siemens


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.